JPMorgan Chase & Co. Raises Myriad Genetics (NASDAQ:MYGN) Price Target to $20.00
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective boosted by equities research analysts at JPMorgan Chase & Co. from $17.00 to $20.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a […]
More Stories
Iran-Backed Forces in Iraq Claim Missile, Drone Attacks on Israel
By Melanie Sun The Iran-backed Islamic Resistance in Iraq (ISI) claimed responsibility on Sunday for launching cruise missiles and drones...
An Overview of Significant Events on Road to Election and Beyond
By Stacy Robinson We’ve entered the final phase of the 2024 election cycle, which has been marked by twists and...
Marathon Digital (NASDAQ:MARA) Stock Price Down 0.8% on Insider Selling
Shares of Marathon Digital Holdings, Inc. (NASDAQ:MARA – Get Free Report) were down 0.8% during trading on Friday after an...
Invesco Municipal Strategic Income ETF (BATS:IMSI) Announces Dividend Increase – $0.17 Per Share
Invesco Municipal Strategic Income ETF (BATS:IMSI – Get Free Report) declared a dividend on Friday, September 20th, NASDAQ reports. Stockholders...
Southern Cross Electrical Engineering Limited (ASX:SXE) Plans Dividend Increase – $0.05 Per Share
Southern Cross Electrical Engineering Limited (ASX:SXE – Get Free Report) announced a final dividend on Thursday, September 19th, MarketIndexAU reports....
Regency Centers (NASDAQ:REG) Updates FY 2024 Earnings Guidance
Regency Centers (NASDAQ:REG – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The...